CD74 is a suitable target for ADCs in some solid tumor xenografts, with efficacy largely influenced by uniformity of CD74 expression and with SN-38 conjugates providing the best therapeutic responses; SN38 conjugates were preferable in solid cancers, such as melanoma, hepatoma, pancreatic, and gastric, whereas doxorubicin ADC was better in lymphoma [79]. Here, CD74 is linked to melanoma.